血浆sFas和sTNFRⅠ在急性白血病中的临床意义

The Clinical Significance of Plasma sFas and sTNFRⅠ in Patients with Acute Leukemia

目的探过急性白血病(AL)患者血浆可溶性Fas(sFas)及可溶性肿瘤坏死因子受体Ⅰ(sTNFRⅠ)水平及其临床意义。方法采用双抗体夹心ELISA法对60例初治AL患者血浆sFas和sTNFRⅠ进行测定,另设10名健康献血员为对照。结果初治AL的sFas和sTNFRⅠ均明显高于正常对照(P<0.01);治疗缓解后,sFas水平显著低于治疗前(P<0.01);血浆(TNFⅠ)水平与急性粒细胞性白血病(ANLL)亚型、反映肿瘤负荷的指标、临床预后、染色体核型相关。结论血浆sFas和sTNFRⅠ可作为白血病发生、转归和预后的指标。

Objective To explore the levels of plasma sFas and sTNFRⅠ in acute leukemia and their clinical significance. Methods Plasma levels of sFas and sTNFRⅠ were measured by ELISA in 60 patients with acute leukemia and 10 normals.Results Plasma levels of sFas and sTNFRI in untreated AL patients were significantly higher than that in the controls(P<0.01).The sFas was lower than that before after CR (P<0.01). The level of sTNFRⅠ in AL patients was related to ANLL subtype,rumor load,clinical prognosis and chromosome type.[WTHZ]Conclusion [WTBZ]Plasma levels of sFas and sTNFRI can reflect the occurrence,the outcome,prognosis of leukemia.